Product structure enriches Dali pharmaceutical industry and promotes the market of chronic disease treatment

[China Pharmaceutical network enterprise news] under the condition that the market competitors are relatively stable, Dali pharmaceutical industry has maintained a relatively stable market share and revenue level in recent years, with considerable operating revenue and profit, with an average annual operating profit of more than 60 million Dali pharmaceutical is mainly engaged in the production and sales of Chinese and Western medicine injections The core products Xingnaojing and Shenmai injection are the top ten varieties of cardiovascular and cerebrovascular drugs in China, and they have the characteristics of armillarisin a, Cytidine Diphosphate Choline and other products In recent years, the Chinese patent medicine industry has made rapid development in China According to the report of intellectual research, the annual compound growth rate of the total sales of Chinese patent medicine in 2011-2015 is 11.16%, and the annual compound growth rate of the total profits is 26.6% The gross profit rate is higher than the average level of the pharmaceutical manufacturing industry In the future, the Chinese patent medicine industry in China will use more modern scientific and technological methods and pharmaceutical means to develop new modern Chinese medicine and natural drugs, and gradually realize the modernization and internationalization of traditional Chinese medicine In the subdivision field, two core products of Dali pharmaceutical industry, "Xingnaojing Injection" and "Shenmai Injection", play an important role in the field of cardiovascular and cerebrovascular traditional Chinese medicine injection Through the public issuance of shares, 262 million yuan was raised to increase the main business, providing a solid foundation for further market development and product competitiveness Traditional Chinese medicine is indispensable for chronic disease treatment The majority of cardiovascular and cerebrovascular diseases are long-term chronic diseases, and Chinese patent medicine has unique advantages in treatment Therefore, Chinese patent medicine for cardiovascular and cerebrovascular diseases occupies an important position in the hospital terminal Chinese patent medicine market According to the statistical data of mienei network, its market share in public hospitals in key cities accounted for 34.47% in 2015, which is a drug with high market share Dali pharmaceutical is mainly engaged in the production and sales of Chinese and Western medicine injections The core products Xingnaojing and Shenmai injection are the top ten varieties of cardiovascular and cerebrovascular drugs in China, and they have the characteristics of armillarisin a, Cytidine Diphosphate Choline and other products Xingnaojing injection drug for cerebrovascular diseases is a class B product of Chinese patent medicine of national medical insurance, which mainly treats stroke coma, cerebral embolism, acute stage of cerebral hemorrhage and brain injury caused by cerebral blood stasis; Shenmai injection is used for cardiovascular diseases It is a kind of national basic medicine catalogue and a class a product of Chinese patent medicine under national medical insurance It mainly treats shock, coronary heart disease, viral myocarditis, chronic cor pulmonale, granulocytopenia, and can improve the immune function of tumor patients At present, there are only three enterprises producing Xingnaojing injection and only seven enterprises mainly producing Shenmai injection Under the condition of relatively stable market competitors, Dali pharmaceutical has maintained a relatively stable market share and revenue level in recent years, with considerable operating revenue and profit, and average annual operating profit of more than 60 million In the project of raising funds, Dali pharmaceutical focuses on the modernization development of traditional Chinese medicine injection and the construction of drug R & D technology center Among them, the second development project of traditional Chinese medicine injection will realize the pharmaceutical technology upgrading of Xingnaojing injection and Shenmai injection, improve the quality standard and production process of traditional Chinese medicine injection, enhance the safety and effectiveness of Dali pharmaceutical products, expand the market share of large varieties of Chinese medicine, so as to promote the healthy development of traditional Chinese medicine industry, consolidate and improve Dali Market competitiveness of pharmaceutical products Based on the increasing production capacity of Xingnaojing injection and the expanding market scale of Shenmai injection, Dali pharmaceutical continues to enrich its product line around the core of promoting blood circulation and removing stasis, strengthening and consolidating the capital Astragalus injection, which is used to regulate the deficiency of heart qi, has increased the gross profit rate of its products after entering the national low-cost drug catalog, bringing more profits to the enterprise At the end of 2016, armillarisin a injection for acute and chronic cholecystitis was added as a local medical insurance product in Yunnan, and its sales volume was improved Dali pharmaceutical has a drug approval number of 10ml: 5mg In terms of brain medicine, Dali pharmaceutical industry has formed a rich product chain Chinese patent medicines include Xingnaojing injection, Cytidine Diphosphate Choline injection and ganglioside injection After years of R & D and accumulation, Dali pharmaceutical has 29 items in total, including 8 inventions, 14 utility models, 7 designs, and the company's "Zhongjing" trademark is Danshen injection, Chaihu Injection, Houttuynia cordata injection, Xiangdan injection and Cytidine Diphosphate Choline injection are all unproductive varieties within the validity period of the drug approval certificate According to the market demand, Dali pharmaceutical industry began to resume the production of Cytidine Diphosphate Choline injection, which was used to treat acute brain injury and consciousness disorder after brain surgery, and has entered the newly adjusted medical insurance catalogue of many provinces At the clinical trial stage, Dali pharmaceutical focuses on the development of ganglioside injection, which is used to treat vascular or traumatic central nervous system injury It is one of the largest single products in China and has a good market prospect By increasing R & D investment, we can build our own R & D system and external scientific research institutions In the form of cooperation, Dali pharmaceutical will speed up the development of new products, further enrich the product structure of the company, actively develop to the direction of traditional Chinese medicine oral preparation, chemical medicine, biochemical preparation, develop the treatment of cancer, diabetes, nervous system and other major diseases, form a product portfolio with sustainable development ability, echelon and series, and ensure the future sustainability of Dali pharmaceutical Ability to grow Original title: holding two major products, Dali pharmaceutical industry develops the market of chronic disease treatment, teaching you to use app (Pharma) and seize the opportunity of pharmaceutical machinery